Abstract 16P
Background
Small cell lung cancer (SCLC) is characterised by TP53 and RB1 loss and amplification of MYC in approximately 30% of patients. Our group and others have shown that DNA damaging therapies (chemotherapy, radiotherapy, or DDR inhibitors, DDRi) synergize with immune checkpoint inhibition in SCLC in vivo models by activating a Stimulator of Interferon Genes (STING)-mediated innate immune response. Also, the transcription factor MYC is known to be positively correlated with the expression of CXCL10 and CCL5, the two downstream chemokines of STING pathway, in SCLC clinical datasets. Based on these findings, we hypothesised that the expression of MYC family members defines distinct molecular states that may be associated with unique responses to treatment with DDRi.
Methods
We explored the landscape of DDR pathways, STING, and immune-related cytokines expression both at mRNA and protein expression levels among a panel of n=9 SCLC cell lines classified as MYChigh or MYClow. We then tested the two SCLC cell line subsets for micronucleus (MN) formation and innate immune activation in response to cisplatin 0.5 μM and/or DNA-PK inhibitor (DNA-PKi) 2 μM.
Results
STING and PD-L1 mRNA expression were higher in MYChigh cells as compared to MYClow SCLC cells (p=0.02). Also, in cisplatin-treated SCLC panel, we found that DDR pathway promoted STING upregulation preferentially in MYChigh subset. In parallel, in vitro treatment with DNA-PKi further increased STING expression in MYChigh cells while reduced or had no effect on STING in MYClow SCLC cells. MN assay showed increased MN formation, particularly in DNA-PKi treated MYChigh cells, resulting in cytosolic DNA release and STING pathway activation. Furthermore, DNA damage accumulation by DNA-PKi promoted tumor recognition and NK cell activity by inducing tumor cell display of NKG2D ligands MICA/B and ULBP1/2/3. Overall, MYChigh cells were more responsive to innate immune cell activity possibly due to higher baseline levels of replication stress.
Conclusions
Our study report that c-MYC expression levels in SCLC cells differentially impact DNA-PK inhibition-mediated activation of STING pathway and presents STING as a downstream of targetable DDR pathway that could offer therapeutic benefit in a subset of MYChigh SCLC patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract